Pramana Pharmaceuticals Inc.
$136,500.00 CAD
≈ 21 months of average Canadian pay
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2020-2021
- Agreement period
- July 1, 2020 – March 31, 2021
- Reference
- nrc-cnrc:172-2020-2021-Q2-953841
Published purpose
A lead optimization study to define a clinical candidate amongst a novel series of GPR119 agonists for the treatment of Type2 Diabetes and co-morbidities. This study has the potential to lead to the development of a first in class therapeutic for T2DM and obesity and advancement of a novel therapeutic pipeline to address co-morbidities associated with GPR119 dysregulation including NASH.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.
Good value
Local impact
Needs context
Questionable
Success story
Wasteful
View official source record
Imported August 10, 2026 from open.canada.ca Grants & Contributions